for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

GlaxoSmithKline plc

GSK.L

Latest Trade

1,555.20GBp

Change

5.20(+0.34%)

Volume

4,210,773

Today's Range

1,546.20

 - 

1,564.40

52 Week Range

1,328.19

 - 

1,857.00

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
1,550.00
Open
1,557.00
Volume
4,210,773
3M AVG Volume
149.22
Today's High
1,564.40
Today's Low
1,546.20
52 Week High
1,857.00
52 Week Low
1,328.19
Shares Out (MIL)
5,017.35
Market Cap (MIL)
78,029.79
Forward P/E
13.19
Dividend (Yield %)
6.37

Next Event

Dividend For GSK.L - 19.0000 GBX

Latest Developments

More

ViiV Healthcare Announces FDA Approval Of An Expanded Indication For Dovato

GSK Says FDA Approves GSK's BLENREP For Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma

GSK says Sanofi, Co In Advanced Discussions With EU To Supply Up To 300 Mln Doses Of Covid-19 Vaccine

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About GlaxoSmithKline plc

GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.

Industry

Biotechnology & Drugs

Contact Info

G S K House, 980 Great West Road

TW8 9GS

United Kingdom

+44.20.80475000

https://www.gsk.com/

Executive Leadership

Jonathan Richard Symonds

Independent Non-Executive Chairman of the Board

Emma N. Walmsley

Chief Executive Officer, Executive Director

Iain James Mackay

Chief Financial Officer, Executive Director

Roger G. Connor

President - Vaccines

Brian McNamara

Chief Executive Officer - GSK Consumer Healthcare

Key Stats

2.54 mean rating - 26 analysts
Sell
Hold
Buy
Revenue (MM, GBP)

2017

30.2K

2018

30.8K

2019

33.8K

2020(E)

35.2K
EPS (GBp)

2017

111.800

2018

119.400

2019

123.900

2020(E)

117.975
Price To Earnings (TTM)
11.70
Price To Sales (TTM)
2.23
Price To Book (MRQ)
5.67
Price To Cash Flow (TTM)
9.83
Total Debt To Equity (MRQ)
233.13
LT Debt To Equity (MRQ)
189.26
Return on Investment (TTM)
15.87
Return on Equity (TTM)
9.92

Latest News

Latest News

U.S. FDA approves GlaxoSmithKline's blood cancer drug

The U.S. Food and Drug Administration on Wednesday approved GlaxoSmithKline's experimental treatment for a common form of blood cancer.

U.S. to pay $2.1 billion to Sanofi, GSK, in COVID-19 vaccine deal

The U.S. government will pay $2.1 billion to Sanofi SA and GlaxoSmithKline Plc for COVID-19 vaccines to cover 50 million people and to underwrite the drug makers' testing and manufacturing, the companies said on Friday.

U.S. to pay $2.1 billion to Sanofi, GSK, in COVID-19 vaccine deal

The U.S. government will pay $2.1 billion to Sanofi SA and GlaxoSmithKline Plc for COVID-19 vaccines to cover 50 million people and to underwrite the drugmakers' testing and manufacturing, the companies said on Friday.

Sanofi, Glaxo advance talks to supply up to 300 million COVID-19 vaccine doses to Europe: companies

Sanofi SA <SASY.PA> and GlaxoSmithKline Plc <GSK.L> on Friday said they are in advanced discussions with the European Commission to supply up to 300 million doses of the drugmakers's experimental COVID-19 vaccine.

FACTBOX-U.S. pours billions into securing access to coronavirus vaccine candidates

As drugmakers race to develop vaccines and therapies for the novel coronavirus, the United States is rushing to secure access to them. The U.S. government has agreed to invest more than $7 billion in vaccines and has funded more than 30 projects, including for diagnostics...

U.S. to pay $2.1 bln to Sanofi, GSK, in COVID-19 vaccine deal

The U.S. government will pay $2.1 billion to Sanofi SA and GlaxoSmithKline Plc for COVID-19 vaccines to cover 50 million people and to underwrite the drug makers' testing and manufacturing, the companies said on Friday.

FACTBOX- The race for a coronavirus vaccine

(Adds Osaka University, Kentucky Bioprocessing, Vaxine, Medigen; Updates CureVac, J&J, GSK) July 29 (Reuters) - More than 150 vaccines are being developed and tested around the world to stop the COVID-19 pandemic, with 25 in human clinical trials, according to the World...

Britain secures 60 million doses of Sanofi/GSK coronavirus vaccine

Britain has signed a deal for up to 60 million doses of a potential coronavirus vaccine being developed by Sanofi and GlaxoSmithKline (GSK), it said on Wednesday, its latest such arrangement as the race to tame the pandemic heats up.

BRIEF-GSK Q2 Adjusted EPS 19.2 Pence

* GSK - CONTINUE TO BELIEVE THAT MULTIPLE OPTIONS WILL BE NEEDED TO PREVENT AND TREAT COVID-19

Britain signs supply deal for 60 mln doses of Sanofi/GSK COVID-19 vaccine

Britain on Wednesday said it had signed a supply deal for up to 60 million doses of a possible COVID-19 vaccine being developed by Sanofi and GlaxoSmithKline, the fourth such deal it has struck.

GSK's blood cancer drug wins European panel thumbs-up

A panel of the European Medicines Agency (EMA) on Friday has recommended approving GlaxoSmithKline's experimental treatment for a common form of blood cancer, days after a similar nod from a U.S. Food and Drug Administration panel.

GSK's blood cancer drug wins European panel thumbs-up

GlaxoSmithKline's experimental treatment for a common form of blood cancer won marketing approval from a European Medicines Agency (EMA) panel on Friday.

BRIEF-GSK To Invest 130 Mln Stg In CureVac Under New Collaboration

* GSK TO MAKE EQUITY INVESTMENT OF £130M (EUR 150M) IN CUREVAC, AND AN UPFRONT PAYMENT OF £104M (EUR 120M)

London stocks gain on vaccine hopes, GlaxoSmithKline boost

London-listed shares rose on Wednesday as signs of progress in developing a COVID-19 vaccine bolstered hopes of a swift post-pandemic economic rebound, while GlaxoSmithKline gained after a U.S. health panel voted in favour of its blood cancer drug.

FDA panel votes in favor of approving GSK's multiple myeloma drug

An independent panel to the U.S. Food and Drug Administration on Tuesday voted in favor of approving GlaxoSmithKline's experimental treatment for a common form of blood cancer, saying the benefits of the treatment outweigh the risks.

FDA panel votes in favor of approving GSK's multiple myeloma drug

An independent panel to the U.S. Food and Drug Administration on Tuesday voted in favor of approving GlaxoSmithKline's experimental treatment for a common form of blood cancer, saying the benefits of the treatment outweigh the risks.

FDA unclear if benefits of GSK multiple myeloma drug outweigh risks

The U.S. Food and Drug Administration said on Friday it was unclear whether the benefits of GlaxoSmithKline's experimental treatment for a common form of blood cancer outweigh the risks ahead of a review of a side-effect which affects the eyes.

FDA says to review side effect of GSK's multiple myeloma drug

The U.S. Food and Drug Administration on Friday said it would review GlaxoSmithKline's experimental treatment for multiple myeloma, a common form of blood cancer, for a reported side-effect which affects the eyes of patients.

BRIEF-GSK And Medicago To Collaborate On Developing Novel Adjuvanted Covid-19 Candidate Vaccine

* GSK AND MEDICAGO ANNOUNCE COLLABORATION TO DEVELOP A NOVEL ADJUVANTED COVID-19 CANDIDATE VACCINE

Britain nears 500 million stg supply deal for Sanofi/GSK COVID-19 vaccine - Sunday Times

Britain is close to agreeing a 500 million pound ($624 million) supply deal with Sanofi and GlaxoSmithKline for 60 million doses of their potential COVID-19 vaccine, the Sunday Times reported.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up